患有外围动脉疾病的患者对抗血栓治疗的药物坚持:系统性审查
Emilien Cj Wegerif1, Barend M Mol2, Çağdaş Ünlü3
1Vascular Surgery, University Medical Centre Utrecht, Utrecht, The Netherlands e.c.j.wegerif@umcutrecht.nl.
药物坚持不良影响大约三分之一的外周动脉疾病 (PAD) 患者接受抗血栓治疗 (ATT). 随着治疗持续时间的延长,坚持治疗的挑战会增加,这构成了重大的公共卫生问题.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 抗血栓治疗 (ATT) 对于预防外周动脉疾病 (PAD) 患者的动脉动脉事件 (AE) 至关重要.
- 药物坚持不良 (MA) 可以显著损害ATT的有效性.
- 了解PAD中不良MA的患病率对于优化患者的治疗结果至关重要.
研究的目的:
- 确定PAD患者中MA对ATT表现较差的患者比例.
- 综合使用患者报告,药房报告或实验室报告的MA结果测量的研究结果.
主要方法:
- 在遵守PRISMA指南的基础上进行系统审查.
- 搜索了PubMed,EMBASE和Cochrane图书馆 (2000年至2023年6月) 的相关研究.
- 包括PAD患者报告MA到ATT的研究;使用既有工具评估偏差风险.
主要成果:
- 包括10项研究 (32,628名患者),设计异质,偏差风险中等.
- 糟糕的MA率差异很大,从2%到45%.
- 在随访时间较长和药房报告结果的研究中观察到较高的不良MA率.
结论:
- 糟糕的MA影响大约三分之一的PAD患者在ATT.
- 随着治疗持续时间的延长,MA的挑战似乎会升级.
- 改善PAD患者的MA对于减少AE至关重要,需要更大的临床和研究重点.
更多相关视频
08:42Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research
Published on: October 22, 2014
10:50Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
Published on: June 29, 2013
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drug Therapy
Antianxiety Medications
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Pre-Procedural Guidelines for Assessing Blood Pressure
Anticoagulant Drugs: Low-Molecular-Weight Heparins
